Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Change in Accured Expenses (2019 - 2025)

Korro Bio's Change in Accured Expenses history spans 7 years, with the latest figure at $1.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 119.85% year-over-year to $1.8 million, compared with a TTM value of $1.4 million through Dec 2025, up 136.05%, and an annual FY2025 reading of $1.4 million, up 136.05% over the prior year.
  • Change in Accured Expenses for Q4 2025 was $1.8 million at Korro Bio, up from $189000.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $2.0 million in Q2 2025, with the low at -$5.0 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is -$85250.0, with a median of $544000.0 recorded in 2022.
  • Year-over-year, Change in Accured Expenses surged 767.11% in 2023 and then crashed 351.92% in 2024.
  • Tracing KRRO's Change in Accured Expenses over 5 years: stood at $804000.0 in 2021, then crashed by 55.6% to $357000.0 in 2022, then plummeted by 228.85% to -$460000.0 in 2023, then soared by 273.04% to $796000.0 in 2024, then skyrocketed by 119.85% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for KRRO's Change in Accured Expenses are $1.8 million (Q4 2025), $189000.0 (Q3 2025), and $2.0 million (Q2 2025).